Maria Dmitrievna Fedorova

Maria Dmitrievna Fedorova

Auto-generated profile, based on publicly available information

Maria Dmitrievna Fedorova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2022 in Problems of Virology
Verified
Journal Article
Open access
PDF file
NKNatalia P. Kisseljova
Natalia P. Kisseljova
MFMaria D. Fedorova
Maria D. Fedorova
AZAnastasia E. Zaikina
Anastasia E. Zaikina
NENadezhda V. Elkina
Nadezhda V. Elkina
EGEkaterina E. Goldobina
Ekaterina E. Goldobina
SVSvetlana Vinokurova
Svetlana Vinokurova
Introduction. High carcinogenic-risk human papillomaviruses (hrHPVs) are recognized as etiological agents of cervical cancer. Constant expression of the viral oncoproteins, E6 and E7, is required for maintenance of the malignant phenotype of tumor cells. The exact mechanism of regulation of viral oncogenes expression in tumor cells is not fully elucidated. The purpose: identification of viral noncoding RNAs (ncRNAs) in HPV16-positve cervical cancer. Materials and methods. The reverse transcription polymerase chain reactions were used to detect viral ncRNAs in HPV16-positve primary cervical squamous cell carcinomas and SiHa and CasKi cell lines. The knockdown technique with oligonucleotides complementary to ncRNAs was used to elucidate their functions. Results. We have identified ncRNAs transcribed in the upstream regulatory region of HPV16 in the cervical carcinoma cell lines and in 32 out 32 cervical squamous cell carcinomas with episomal or integrated forms of HPV16 DNA. Knockdown of sense or antisense strains of ncRNAs by oligonucleotides results in a decrease or increase of the E6 and E7 oncogenes mRNA levels in cells, respectively. These changes of oncogenes mRNA levels are accompanied by the modulation of the levels of the p53 protein, the main target of the E6 oncoprotein. Conclusion. The presence of regulatory ncRNAs in all examined tumors and cell lines revealed for the first time indicates their necessity for maintenance of constant expression of E6 and E7 oncogenes in them. The findings can be useful for understanding of the fundamental aspects of the viral expression regulation in HPV16-positive tumors.

15 December 2018 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
PAP. M. Abramov
P. M. Abramov
AKA. N. Katargin
A. N. Katargin
MFM. D. Fedorova
M. D. Fedorova
NKN. P. Kisseljova
N. P. Kisseljova
LPL. S. Pavlova
L. S. Pavlova
SVSvetlana Vinokurova
Svetlana Vinokurova
Background. Overexpression of the human papillomavirus oncogenes E6 and E7 is a major factor in initiation and progression of HPV-induced tumors. Inactivation of negative regulatory function of E2 protein – the main viral transcription and replication regulator – is considered to be an important mechanism leading to the viral oncogenes overexpression. It is known that the loss of E2 functions occurs due to disruption of E2 open reading frame during the viral DNA integration into a cell genome in a part of HPV-positive tumors. An alternative mechanism of E2 function blocking in tumors retained its expression can be methylation of the HPV regulatory region, since it is known that E2 is incapable to bind its methylated binding sites.The study objective is to analyze methylation of the HPV16 regulatory region and expression of the viral E6 and E7 oncogenes in E2 expressing or non-expressing clinical samples of cervical cancer.Results. It has been demonstrated that the level of the HPV16 URR methylation in E2-expressing lesions is significantly higher than that in non-expressing cervical cancer lesions. Demethylation of the HPV16 promoter in cervical cell line Caski is followed by decrease of the viral E6 и E7 oncogenes mRNA levels, supporting the hypothesis that methylation is necessary for effective E6 and E7 transcription and indicates on restitution of E2 regulatory function in E2-expressing cervical cancer cells.Conclusion. These data suggest that methylation of E2 binding sites in HPV16 regulatory region blocking E2 protein binding represents an important mechanism ensuring high level of the viral E6 and E7 oncogenes expression.

21 December 2024 in Russian Journal of Oncology
Verified
Journal Article
Open access
PDF file
NENadezhda V. Elkina
Nadezhda V. Elkina
MFMariya D. Fedorova
Mariya D. Fedorova
RFRadik S. Faskhutdinov
Radik S. Faskhutdinov
IIIuliia O. Iurchenko
Iuliia O. Iurchenko
KZKirill I. Zhordania
Kirill I. Zhordania
ЮОЮрченко Юлия Олеговна
Юрченко Юлия Олеговна
BACKGROUND: Cervical cancer (CC) is the fourth most common cancer among women worldwide in terms of incidence and mortality. High-risk human papillomaviruses (HPVs) are etiologic factor of CC in more than 90% of cases, with type 16 HPV (HPV16) revealed in 50% of cancers. Dysregulation of expression of viral oncogenes E6 and E7 is the main cause of malignant transformation in infected cervical epithelial cells. The mechanisms of impaired expression of these genes are still underexplored. The dysfunction of viral microRNAs may be among the underlying factors. AIM: To analyze the expression of HPV16-associated microRNA-H1 and microRNA-H2 in cervical cancer specimens, evaluate the correlation of their expression to viral load and overall patient survival, and analyze in silico their potential viral and cellular targets. MATERIALS AND METHODS: The expression of HPV16 microRNA-H1 and HPV16 microRNA-H2 was evaluated in the real-time polymerase chain reaction. With this purpose, small RNAs were isolated from 36 specimens of HPV16-positive squamous cell carcinomas of the cervix. Further, the viral load was assessed after calculating the value of HPV16 DNA copies per cell. The association between microRNA expression and the viral load was evaluated using the nonparametric Spearman’s correlation coefficient. Kaplan-Meier curves were plotted to analyze the dependence of 5-year overall survival on the level of viral microRNA expression. The miRanda algorithm and online services mirDB, MR-microT and TargetScan Custom 5.2 were used for in silico search of theoretical microRNA targets. RESULTS: MicroRNA-H1 expression was revealed in 33 of 38 specimens (86.8%), microRNA-H2 was detected in 37 of 38 specimens (97.4%) of HPV16-positive cervical cancer. There was a positive correlation between both microRNA-H1 (r=0.36, p=0.042) and microRNA-H2 (r=0.51, p=0.001) expression and HPV16 viral load. Higher level of expression of viral microRNA-H1 and microRNA-H2 tended to correlate with better overall patient survival. The theoretical microRNA-H1 (E7, E2, E5, L2 and URR) and microRNA-H2 (E1, E2, E5, L2, L1, URR) targets in the HPV16 genome were identified in silico, as well as theoretical cellular targets indicating possible regulation of cellular signaling pathways by means of viral microRNAs, both controlling normal viral cycle and promoting tumor transformation. CONCLUSION: The results of this study demonstrate promising further investigation of the functions of viral microRNAs in relation with the infectious process and virus-induced malignant transformation, and their potential importance in the diagnosis of HPV16-associated cancers.

15 September 2024 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
DED. S. Elkin
D. S. Elkin
MTM. I. Taubinskaya
M. I. Taubinskaya
NENadezhda V. Elkina
Nadezhda V. Elkina
RFR. S. Faskhutdinov
R. S. Faskhutdinov
MFM. D. Fedorova
M. D. Fedorova
SVSvetlana Vinokurova
Svetlana Vinokurova
Introduction. Human papillomavirus (HPV) infection with high-risk HPVs is an etiological factor in the development of cervical cancer, with HPV type 16 (HPV16) being the most common. The mechanisms leading to disruption of viral oncogene expression and initiation of epithelial cell transformation are poorly understood. Epigenetic regulatory factors, including cellular miRNAs, may play an important role in HPV-induced carcinogenesis, and aberrantly expressed miRNAs may be promising markers for the diagnosis of HPV-associated lesions.Aim. To search for miRNAs involved in the pathogenesis of HPV16-associated cervical cancer and to evaluate their diagnostic potential for the detection of cervical cancer and precancerous lesions.Materials and methods. MiRNA expression in clinical samples was assessed by both next generation sequencing and quantitative stem-loop polymerase chain reaction (sl-qPCR). Plasma miRNAs from patients with precancerous and cancerous lesions and healthy donors were analyzed using sl-qPCR. Loss of heterozygosity in cervical cancer samples was assessed by copy number ratio of MIR135A1 and ACTB genes. A total of 67 patients with cervical cancer, 21 with precancerous cervical lesions and 24 healthy donors were included in the study. The effect of DNA methylation on miRNA-135A1 expression was evaluated after treatment with a demethylating agent of the cervical HPV16-positive SiHa cell line. Changes in the expression of the HPV16 E6 oncogene were analyzed after transfection with synthetic analogues of the mature forms of miRNA-135А1 (miRNA-135a-3p and miRNA-135a-5p).Results. A significant decrease in the expression of miRNA-135A1 and miRNA-135A2 was detected in tumor tissue samples from HPV16-positive cervical cancer, which was confirmed by sl-qPCR in an independent panel of tumor samples. A decrease in miRNA-135A1 expression was shown to result from both loss of heterozygosity of the gene and aberrant DNA methylation. Transfection of mature forms of miRNA-135A1 into SiHa cells resulted in decreased expression of the E6 oncogene of HPV16. Blood plasma samples from patients with cervical cancer and precancerous lesions showed lower levels of miRNA-135a-3p than healthy donors, and ROC analysis indicated its high diagnostic potential.Conclusion. Levels of miRNA-135A1 are significantly reduced in cervical lesions, both in tumor tissue and plasma, and the ability of this miRNA to suppress the expression of the HPV16 E6 oncogene suggests its oncosuppressive properties. Thus, miRNA-135A1 can be used as a promising new marker for the diagnosis of HPV-associated lesions.

15 December 2019 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
NLN. L. Lazarevich
N. L. Lazarevich
PAP. M. Abramov
P. M. Abramov
MFM. D. Fedorova
M. D. Fedorova
IKI. F. Kustova
I. F. Kustova
DSD. A. Shavochkina
D. A. Shavochkina
ЮПЮ. И. Патютко
Ю. И. Патютко
Background. Over 600,000 people die from hepatocellular carcinoma (HCC) each year worldwide. The disease is often detected at advanced stages and in many cases is not curable. Early diagnostic and monitoring of HCC recurrences remains a substantial problem in clinical oncology. That determines the need for a search for highly sensitive and specific biomarkers for the non-invasive of HCC diagnostics. The objective of the study. Identification of the hypermethylated locus in the promoter region of the septin 9 (Sept9) gene based on the annotated methylomes from the public databases. Experimental validation of methylation on a pilot panel of paired clinical samples of patients with HCC, as well as tissue samples from patients with benign liver tumors and lymphocytes from healthy donors. Materials and methods. To analyze the methyl data, samples of HCC from TCGA, hepatocellular adenoma from GEO (Gene Expression Omnibus) depository, peripheral blood cells and tissues of healthy donors from Methbank were used. Experimental validation of methylation levels of the identified site was carried out on a pilot panel of clinical samples by bisulphite pyrosequencing using PyroMark Q24.Results. Based on the analysis of methylome data, we selected cg20275528 site, which is characterized by high level of methylation in HCC tissues and minimal levels of methylation in non-tumor liver tissue, hepatocellular adenoma and peripheral blood of healthy donors. Experimental testing on a pilot panel of clinical specimens showed that the level of marker site methylation in HCC (42 % median) is significantly higher than in non-tumor liver tissues (3 % median) and benign neoplasms (1.5 % median) and exceeds the threshold value in HCC compared to paired samples of adjacent non-tumor liver tissue in 20 out of 30 studied cases (66.6 %). The general possibility for cg20275528 methylation detection in circulating DNA of plasma in HCC patients was shown.Conclusion. The obtained results indicate that the approach to the detection and experimental verification of diagnostically significant markers developed and tested in this study can be used to identify new differentially methylated sites and to establish new approaches for non-invasive HCC diagnosis.

6 August 2025 in Cancer Urology
Verified
Journal Article
Open access
PDF file
KNK. S. Nemtseva
K. S. Nemtseva
VMV. B. Matveev
V. B. Matveev
NENadezhda V. Elkina
Nadezhda V. Elkina
MFM. D. Fedorova
M. D. Fedorova
DED. S. Elkin
D. S. Elkin
SVSvetlana Vinokurova
Svetlana Vinokurova
Aim. Search for new microRNAs as markers for differential diagnosis of teratoma and live tumor tissues.Materials and methods. In the study, freshly frozen tissue samples obtained after orchifuniculectomy (n = 46) and retroperitoneal lymph node dissection (n = 42) in patients with TGCT diagnosis were analyzed. MicroRNAs were isolated from tissue samples and analyzed using reverse transcription polymerase chain reaction.Results. After studying the Cancer Genome Atlas, microRNA-196a-5p and microRNA-200b-3p with differential expression in tissue samples of different histological types of TGCT were identified. These microRNA are significantly overexpressed in non-seminomas, and their expression levels significantly differ from expression levels in normal tissues and seminomas. The level of microRNA-196b-5p expression in teratomas obtained after retroperitoneal lymph node dissection is significantly higher than in seminomas, and microRNA-200b-3p expression level is significantly higher than in tissues with necrotic changes. ROC analysis has shown 89 % sensitivity and 79 % specificity for microRNA-196b-5p as a diagnostic marker. For microRNA-200b-3p, sensitivity and specificity were 75 and 89 %, respectively.Conclusion. In this study, we have shown for the first time that microRNA-196a-5p and microRNA-200b-3p have high diagnostic potential as markers for identification of various types of TGCTs including teratoma.